Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf483 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Tom Hühne und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics II, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany. Hauptthemen laut MEDLINE: Receptor, Melanocortin, Type 4, Bardet-Biedl Syndrome, alpha-MSH, Kidney. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry of Research and Education, Rhythm Pharmaceuticals.
Abstract (Originalsprache)
Background and Objective The melanocortin-4 receptor agonist setmelanotide compensates for upstream gene defects in the brain leptin-melanocortin pathway and reduces hyperphagia and obesity in selected monogenic obesity forms and Bardet-Biedl syndrome (BBS). We aimed to evaluate the short-term impact of setmelanotide treatment in BBS presenting original real-world data focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) and kidney function.
Methods
This monocentric, prospective observational cohort study was performed between June and December 2023 and included patients above the age of 6 years with genetically confirmed BBS, obesity, and/or hyperphagia and planned setmelanotide therapy. Ultrasound examination of the liver including shear wave elastography, dispersion and attenuation imaging (ATI), a bioimpedance analysis, and a hyperphagia questionnaire survey were applied in addition to clinical data collection.
Results
Twenty-six patients with BBS (mean age 19.2 years, range [6.2; 51.8]; mean body mass index (BMI) z-score 2.95, range [1.32; 4.84]) were included. All were classified with MASLD (54% S3, 23% each S1 and S2). After 6 months of setmelanotide treatment, estimated glomerular filtration rate increased up to 10.1 mL/min/1.73 m² (95% confidence interval (CI) [4.3; 15.9]). The following parameters also improved: BMI z-score −0.5 (95% CI [−0.6; −0.3]); hyperphagia score −12.3 (95% CI [−15.5; −9.0]); total body fat −3.1% (95% CI [−5.7; −0.5]); ATI −0.14 dB/cm/MHZ (95% CI [−0.17; −0.11]). A total of 85% of patients exhibited either resolution of MASLD or stabilization at grade S1. MASLD improvement correlated only with liver size, not BMI reduction.
Conclusion
Setmelanotide treatment is associated with improvement of MASLD independent of BMI reduction as well as increased glomerular filtration rate in BBS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics II, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany.
- Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany.
- Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna 1090, Austria.
- Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam 1105, The Netherlands.
- Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany.
ORCID-Profile: Tom Hühne, Pia Brensing, Lars Dinkelbach, Eva-Maria Huessler, Thomas Scherer, Arend Bökenkamp, Anja Gäckler, Lars Pape, Metin Cetiner
Förderung
- German Federal Ministry of Research and Education
- Rhythm Pharmaceuticals
Zitieren
APA
Hühne, T., Polichronidou, I. M., Finkelberg, I., Brensing, P., Jaegers, J., Dinkelbach, L., Kiewert, C., Galetzka, W., Huessler, E. M., Scherer, T., Bökenkamp, A., Gäckler, A., Pape, L., & Cetiner, M. (2026). Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf483
Vancouver
Hühne T, Polichronidou IM, Finkelberg I, Brensing P, Jaegers J, Dinkelbach L, et al. Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf483
BibTeX
@article{Hhne2026,
author = {Hühne, Tom and Polichronidou, Ioanna Maria and Finkelberg, Ilja and Brensing, Pia and Jaegers, Johannes and Dinkelbach, Lars and Kiewert, Cordula and Galetzka, Wolfgang and Huessler, Eva-Maria and Scherer, Thomas and Bökenkamp, Arend and Gäckler, Anja and Pape, Lars and Cetiner, Metin},
title = {Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf483}
}
EUVIMED